title: Adjuvant efficacy of mOMV against avian influenza virus infection in mice.
abstract: Highly pathogenic avian influenza H5N1 viruses are found chiefly in birds and have caused severe disease and death in infected humans. Development of influenza vaccines capable of inducing heterosubtypic immunity against a broad range of influenza viruses is the best option for the preparedness, since vaccination remains the principal method in controlling influenza viral infections. Here, a mOMV-adjuvanted recombinant H5N2 (rH5N2) whole virus antigen vaccine with A/Environment/Korea/W149/06(H5N1)-derived H5 HA and A/Chicken/Korea/ma116/04(H9N2)-derived N2 NA in the backbone of A/Puerto Rico/8/34(H1N1) was prepared and generated by reverse genetics. Groups of mice were vaccinated by a prime-boost regime with the rH5N2 vaccine (1.75 μg of HA with/without 10 μg mOMV or aluminum hydroxide adjuvant for comparison). At two weeks post-immunizations, vaccinated mice were challenged with lethal doses of 10(3.5) EID50/ml of H5N1 or H9N2 avian influenza viruses, and were monitored for 15 days. Both mOMV- and alum-adjuvant vaccine groups had high survival rates after H5N1 infection and low levels of body weight changes compared to control groups. Interestingly, the mOMV-adjuvanted group induced better cross-reactive antibody responses serologically and promoted cross-protectivity against H5N1 and H9N2 virus challenges. Our results suggest that mOMV could be used as a vaccine adjuvant in the development of effective vaccines used to control influenza A virus transmission.
authors.affiliation: College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, 361-763, Republic of Korea.
authors.forename: Byeong-Jae
authors.initials: BJ
authors.lastname: Lee
authors.forename: Sang-Ho
authors.initials: SH
authors.lastname: Lee
authors.forename: Min-Suk
authors.initials: MS
authors.lastname: Song
authors.forename: Philippe Noriel Q
authors.initials: PN
authors.lastname: Pascua
authors.forename: Hyeok-il
authors.initials: HI
authors.lastname: Kwon
authors.forename: Su-Jin
authors.initials: SJ
authors.lastname: Park
authors.forename: Eun-Ha
authors.initials: EH
authors.lastname: Kim
authors.forename: Arun
authors.initials: A
authors.lastname: Decano
authors.forename: Se Mi
authors.initials: SM
authors.lastname: Kim
authors.forename: Gyo Jin
authors.initials: GJ
authors.lastname: Lim
authors.forename: Doo-Jin
authors.initials: DJ
authors.lastname: Kim
authors.forename: Kyu-Tae
authors.initials: KT
authors.lastname: Chang
authors.forename: Sang-Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Young Ki
authors.initials: YK
authors.lastname: Choi
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000536:Aluminum Hydroxide / Q000008:administration & dosage; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D055252:Cell-Derived Microparticles; D003429:Cross Reactions; D004195:Disease Models, Animal; D053125:Influenza A Virus, H5N2 Subtype / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D059386:Reverse Genetics; D016019:Survival Analysis; D014611:Vaccination / Q000379:methods
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines; D000536:Aluminum Hydroxide